CD4 and autoimmune hepatitis: We previously reported that ERC therapy can ameliorate a variety of immune-related disorders in vivo, including transplant rejection, ulcerative colitis, and autoimmune hepatitis, via modulating CD4+ T cells (Hu et al., 2021; Li et al., 2019; Wang et al., 2021).